Table 4. Characteristics of specific interventions reported in seven or more trial registry entries.

A
Trial intervention	Trial registry entries	Recruitment ongoing	Recruitment completed	Disease specification				Continents					Multicenter
				Prevention	Diagnosed/suspected COVID	Mild/moderate symptoms	Hospitalized/severe/ ICU	Asia	Europe	North America	South America	Africa
	n	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
Chloroquine	113	62 (55%)	7 (6%)	60 (53%)	21 (19%)	15 (13%)	17 (15%)	42 (37%)	24 (21%)	32 (28%)	6 (5%)	4 (4%)	36 (32%)
Convalescent Plasma	64	38 (59%)	5 (8%)	1 (2%)	5 (8%)	5 (8%)	53 (83%)	23 (36%)	11 (17%)	19 (30%)	9 (14%)	2 (3%)	22 (34%)
Stem cells	51	24 (47%)	3 (6%)	1 (2%)	7 (14%)	2 (4%)	41 (80%)	25 (49%)	10 (20%)	10 (20%)	2 (4%)	1 (2%)	9 (18%)
Chloroquine + other	30	17 (57%)	4 (13%)	4 (13%)	5 (17%)	4 (13%)	17 (57%)	12 (40%)	14 (47%)	2 (7%)	0	0	17 (57%)
Chloroquine / Azithromycin	22	9 (41%)	0	2 (9%)	2 (9%)	5 (23%)	13 (59%)	4 (18%)	6 (27%)	8 (36%)	3 (14%)	1 (5%)	7 (32%)
Tocilizumab	19	15 (79%)	0	0	1 (5%)	3 (16%)	15 (79%)	3 (16%)	9 (47%)	4 (21%)	1 (5%)	0	11 (58%)
Favipiravir	19	10 (53%)	2 (11%)	0	2 (11%)	10 (53%)	7 (37%)	13 (68%)	2 (11%)	2 (11%)	0	2 (11%)	7 (37%)
BCG vaccine	17	12 (71%)	0	17 (100%)	0	0	0	3 (18%)	8 (47%)	1 (6%)	2 (12%)	2 (12%)	14 (82%)
Ivermectin	17	9 (53%)	2 (12%)	2 (12%)	2 (12%)	7 (41%)	6 (35%)	7 (41%)	4 (24%)	0	4 (24%)	2 (12%)	5 (29%)
Prone position	16	13 (81%)	0	0	0	3 (19%)	13 (81%)	1 (6%)	6 (38%)	9 (56%)	0	0	7 (44%)
Colchicine	16	15 (94%)	1 (6%)	0	5 (31%)	4 (25%)	7 (44%)	4 (25%)	7 (44%)	4 (25%)	0	0	7 (44%)
Azithromycin	15	8 (53%)	2 (13%)	0	5 (33%)	3 (20%)	7 (47%)	4 (27%)	7 (47%)	2 (13%)	1 (7%)	1 (7%)	6 (40%)
Enoxaparin	11	7 (64%)	0	0	0	4 (36%)	7 (64%)	2 (18%)	4 (36%)	3 (27%)	2 (18%)	0	5 (45%)
Vitamin C	10	2 (20%)	4 (40%)	0	1 (10%)	1 (10%)	8 (80%)	6 (60%)	0	3 (30%)	0	0	1 (10%)
Nitric Oxide	10	5 (50%)	0	1 (10%)	1 (10%)	3 (30%)	5 (50%)	0	0	10 (100%)	0	0	2 (20%)
Ozone autohemotherapy	9	4 (44%)	2 (22%)	0	2 (22%)	1 (11%)	6 (67%)	4 (44%)	4 (44%)	1 (11%)	0	0	2 (22%)
INF-Beta	9	5 (56%)	2 (22%)	0	4 (44%)	1 (11%)	4 (44%)	8 (89%)	1 (11%)	0	0	0	2 (22%)
Glucocorticoid	9	5 (56%)	1 (11%)	0	1 (11%)	1 (11%)	7 (78%)	5 (56%)	2 (22%)	0	2 (22%)	0	3 (33%)
Vitamin D	8	5 (63%)	0	0	2 (25%)	2 (25%)	4 (50%)	1 (13%)	5 (63%)	1 (13%)	1 (13%)	0	3 (38%)
Sarilumab	8	6 (75%)	0	0	1 (13%)	2 (25%)	5 (63%)	0	6 (75%)	2 (25%)	0	0	2 (25%)
Vitamin A	7	2 (29%)	2 (29%)	0	2 (29%)	1 (14%)	4 (57%)	6 (86%)	0	0	0	1 (14%)	1 (14%)
Heparin	7	5 (71%)	0	0	0	0	7 (100%)	0	1 (14%)	5 (71%)	0	0	4 (57%)
B
Trial intervention	Trial registry entries	No. of blinded parties					Sample size				Total participants	Mortality outcome
		None (open label)	1	2	3	4	< 50	50–199	200–999	≥1000		Primary	Secondary	Participants assessed for mortality
	n	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n	n (%)	n (%)	n (%)
Chloroquine	113	41 (36%)	9 (8%)	23 (20%)	9 (8%)	24 (21%)	5 (4%)	25 (22%)	52 (46%)	31 (27%)	199,841	16 (14%)	39 (35%)	51,829 (26%)
Convalescent Plasma	64	37 (58%)	3 (5%)	12 (19%)	7 (11%)	4 (6%)	12 (19%)	33 (52%)	17 (27%)	2 (3%)	11,840	27 (42%)	25 (39%)	10,331 (87%)
Stem cells	51	17 (33%)	4 (8%)	10 (20%)	5 (10%)	10 (20%)	28 (55%)	20 (39%)	3 (6%)	0	3,370	16 (31%)	14 (27%)	2,124 (63%)
Chloroquine + other	30	21 (70%)	0	3 (10%)	2 (7%)	3 (10%)	0	9 (30%)	8 (27%)	13 (43%)	46,944	11 (37%)	12 (40%)	39,314 (84%)
Chloroquine / Azithromycin	22	13 (59%)	1 (5%)	2 (9%)	2 (9%)	4 (18%)	2 (9%)	5 (23%)	11 (50%)	4 (18%)	12,186	5 (23%)	8 (36%)	9,960 (82%)
Tocilizumab	19	10 (53%)	0	7 (37%)	0	1 (5%)	1 (5%)	9 (47%)	9 (47%)	0	4,139	7 (37%)	12 (63%)	4,139 (100%)
Favipiravir	19	14 (74%)	0	4 (21%)	0	0	2 (11%)	12 (63%)	4 (21%)	1 (5%)	3,210	0	8 (42%)	1,232 (38%)
BCG vaccine	17	2 (12%)	4 (24v	3 (18%)	0	8 (47%)	0	0	4 (24%)	13 (76%)	27,262	1 (6%)	10 (59%)	15,616 (57%)
Ivermectin	17	5 (29%)	1 (6%)	7 (41%)	1 (6%)	3 (18%)	3 (18%)	12 (71%)	2 (12%)	0	1,752	1 (6%)	1 (6%)	326 (19%)
Prone position	16	12 (75%)	3 (19%)	1 (6%)	0	0	0	5 (31%)	11 (69%)	0	4,228	8 (50%)	5 (31%)	3,612 (85%)
Colchicine	16	9 (56%)	2 (13%)	3 (19%)	1 (6%)	1 (6%)	1 (6%)	8 (50%)	3 (19%)	4 (25%)	12,268	4 (25%)	6 (38%)	11,624 (95%)
Azithromycin	15	10 (67%)	1 (7%)	1 (7%)	1 (7%)	2 (13%)	1 (7%)	6 (40%)	7 (47%)	1 (7%)	5,591	3 (20%)	8 (53%)	4,893 (88%)
Enoxaparin	11	10 (91%)	1 (9%)	0	0	0	1 (9%)	4 (36%)	3 (27%)	3 (27%)	6,134	5 (45%)	4 (36%)	6,014 (98%)
Vitamin C	10	2 (20%)	1 (10%)	3 (30%)	1 (10%)	3 (30%)	2 (20%)	5 (50%)	3 (30%)	0	1,706	1 (10%)	6 (60%)	1,490 (87%)
Nitric Oxide	10	5 (50%)	1 (10%)	1 (10%)	1 (10%)	2 (20%)	4 (40%)	0	6 (60%)	0	2,082	0	7 (70%)	1,292 (62%)
Ozone autohemotherapy	9	3 (33%)	4 (44%)	1 (11%)	0	0	2 (22%)	6 (67%)	1 (11%)	0	872	1 (11%)	3 (33%)	470 (54%)
INF-Beta	9	4 (44%)	0	2 (22%)	1 (11%)	1 (11%)	3 (33%)	3 (33%)	3 (33%)	0	1,348	1 (11%)	4 (44%)	630 (47%)
Glucocorticoid	9	5 (56%)	1 (11%)	0	0	1 (11%)	1 (11%)	4 (44%)	4 (44%)	0	1,542	3 (33%)	4 (44%)	1,342 (87%)
Vitamin D	8	3 (38%)	0	2 (25%)	0	3 (38%)	0	3 (38%)	2 (25%)	3 (38%)	4,487	4 (50%)	3 (38%)	4,423 (99%)
Sarilumab	8	6 (75%)	0	0	0	2 (25%)	1 (13%)	2 (25%)	5 (63%)	0	1,726	2 (25%)	5 (63%)	1,486 (86%)
Vitamin A	7	5 (71%)	0	1 (14%)	1 (14%)	0	2 (29%)	3 (43%)	2 (29%)	0	1,089	0	2 (29%)	405 (37%)
Heparin	7	2 (29%)	2 (29%)	0	1 (14%)	2 (29%)	0	3 (43%)	3 (43%)	1 (14%)	4,454	3 (43%)	3 (43%)	4,354 (98%)